Recombinant Human LDLR cell lysate

• Cat.No.: LDLR-2780HCL
• Product Overview: Human LDLR / LDL Receptor derived in Human Cells. The whole cell lysate is provided in 1X Sample Buffer.Browse all transfected cell lysate positive controls

Specification

• Source: Human cells
• Species: Human
• Preparation method: Transfected cells were cultured for 48hrs before collection. The cells were lysed in modified RIPA buffer with cocktail of protease inhibitors. Cell debris was removed by centrifugation and then centrifuged to clarify the lysate. The cell lysate was boiled for 5 minutes in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% b-mercaptoethanol, and lyophilized.
• Lysis buffer: Modified RIPA Lysis Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF
• Quality control Testing: 12.5% SDS-PAGE Stained with Coomassie Blue
• Recommended Usage: 1. Centrifuge the tube for a few seconds and ensure the pellet at the bottom of the tube.2. Re-dissolve the pellet using 200μL pure water and boiled for 2-5 min.3. Store it at -80°C. Recommend to aliquot the cell lysate into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.Notes:The lysate is ready to load on SDS-PAGE for Western blot application. If dissociating conditions are required, add reducing agent prior to heating.
• Stability: Samples are stable for up to twelve months from date of receipt at -80°C
• Storage Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF
• Storage Instruction: Lysate samples are stable for 12 months from date of receipt when stored at -80°C. Avoid repeated freeze-thaw cycles. Prior to SDS-PAGE fractionation, boil the lysate for 5 minutes.
• Tag: Non

Gene Information

• Gene Name: LDLR low density lipoprotein receptor [ Homo sapiens ]
• Official Symbol: LDLR
• Synonyms: LDLR; low density lipoprotein receptor; low-density lipoprotein receptor; familial hypercholesterolemia; LDL receptor; low-density lipoprotein receptor class A domain-containing protein 3; FH; FHC; LDLCQ2
• Gene ID: 3949
• mRNA Refseq: NM_000527
• Protein Refseq: NP_000518
• MIM: 606945
• UniProt ID: P01130
• Chromosome Location: 19p13.2
• Pathway: Bile secretion, organism-specific biosystem; Bile secretion, conserved biosystem; Chylomicron-mediated lipid transport, organism-specific biosystem; DNA damage response (only ATM dependent), organism-specific biosystem; Endocytosis, organism-specific biosystem; Endocytosis, conserved biosystem; Hepatitis C, organism-specific biosystem
• Function: calcium ion binding; glycoprotein binding; low-density lipoprotein receptor activity; protein binding; receptor activity; very-low-density lipoprotein particle receptor activity

Reviews

08/11/2020

The LDLR protein stands out for its exceptional quality, making it an excellent choice to meet my experimental requirements.

10/07/2018

Its purity and consistency guarantee reliable and reproducible results, ensuring the reliability of my research outcomes.

03/04/2017

the LDLR protein offers superior quality and reliability, making it a perfect fit for my experimental needs.

Q&As

Are there conditions where upregulation of LDLR might be beneficial?

Yes, conditions where increasing the expression or function of LDLR could potentially aid in reducing circulating LDL cholesterol and minimizing cardiovascular risk.

Are there ongoing research efforts regarding LDLR and its clinical applications?

Yes, research is continually conducted to better understand LDLR-related conditions and to develop more effective treatments, including gene-editing technologies and novel therapies.

What are the clinical implications of LDLR dysfunction?

Dysfunction in LDLR can lead to high levels of LDL cholesterol in the blood, contributing to conditions like familial hypercholesterolemia and an increased risk of heart disease.

How does LDLR impact atherosclerosis?

A dysfunctional LDLR can lead to an accumulation of LDL cholesterol in the arteries, promoting atherosclerosis, the hardening and narrowing of arteries.

What treatment options exist for LDLR-related conditions?

Treatments involve lifestyle changes, cholesterol-lowering medications, and in some cases, gene therapies or specialized medications targeting the LDL receptor.